Buffy coat pooled platelet concentrate: A new age platelet component

BACKGROUND: Buffy coat pooled platelet concentrate (BCPP) is a new blood component mainly used in Europe, which has good attributes of both random donor platelets and apheresis platelets in terms of high platelet count, leukoreduced and available in emergency. We planned this study to compare qualit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rakesh Kumar, Hari Krishan Dhawan, Ratti Ram Sharma, Jyotdeep Kaur
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Medknow Publications 2021
Materias:	buffy coat derived platelet component buffy coat pooled platelet concentrate leukofiltered platelets platelet additive solution Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/93805c7cc7b84529bc97c181e34cd573
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93805c7cc7b84529bc97c181e34cd573
record_format	dspace
spelling	oai:doaj.org-article:93805c7cc7b84529bc97c181e34cd5732021-11-12T10:08:28ZBuffy coat pooled platelet concentrate: A new age platelet component0973-62471998-356510.4103/ajts.AJTS_72_19https://doaj.org/article/93805c7cc7b84529bc97c181e34cd5732021-01-01T00:00:00Zhttp://www.ajts.org/article.asp?issn=0973-6247;year=2021;volume=15;issue=2;spage=125;epage=132;aulast=Kumarhttps://doaj.org/toc/0973-6247https://doaj.org/toc/1998-3565BACKGROUND: Buffy coat pooled platelet concentrate (BCPP) is a new blood component mainly used in Europe, which has good attributes of both random donor platelets and apheresis platelets in terms of high platelet count, leukoreduced and available in emergency. We planned this study to compare quality parameters and biochemical activation markers among buffy coat pooled platelets and apheresis platelet concentrate (AP-PC) to establish the quality and safety of this new blood component during storage.MATERIALS AND METHODS: Three different preparations of BCPP were prepared: Nonleukoreduced (BCPP Part A), leukoreduced (BCPP Part B), and leukoreduced with platelet additive solution (PAS) (BCPP Part C) using a pool of 15 ABO-matched, nonreactive buffy-coats in each experiment to avoid any donor-related variations. Ten such experiments were done. Each BCPP was equivalent to 5 buffy coat units. Ten apheresis platelets were taken as control. Serial samplings were done on day 0, 3, and 5 of collection and were assessed for: volume, platelet count, white blood cell count, swirling, pH, sterility, glucose, lactate, soluble p-selectin, Interleukin (IL)-6, IL-1 β, and tumor necrosis factor alpha (TNF-α).RESULTS: BCPP Part C (leukoreduced with PAS) maintained the best quality parameters in terms of maintenance of pH, least lactate accumulation, least sP-selectin levels, and least accumulation of inflammatory mediators (IL-6, IL-1 β, and TNF-α) than the other groups >BCPP part B >AP-PC and >BCPP Part A. On day 5 of storage pH for BCPP Part A, Part B, Part C, and AP-PC was: 6.33, 6.42, 6.64, and 6.29, respectively, and soluble p-selectin (ng/ml) was 201 ± 22, 186 ± 11, 149 ± 18, 200 ± 23, respectively. BCPP Part B and AP-PC had comparable quality parameters and activation markers.CONCLUSIONS: Buffy coat pooled platelet has comparable and even better-quality control parameters (especially leukofiltered with PAS) than conventional platelet preparation and is a good alternative for meeting platelet transfusion requirements of critical patients during emergency hours in resource-constraint setting.Rakesh KumarHari Krishan DhawanRatti Ram SharmaJyotdeep KaurWolters Kluwer Medknow Publicationsarticlebuffy coat derived platelet componentbuffy coat pooled platelet concentrateleukofiltered plateletsplatelet additive solutionDiseases of the blood and blood-forming organsRC633-647.5ENAsian Journal of Transfusion Science, Vol 15, Iss 2, Pp 125-132 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	buffy coat derived platelet component buffy coat pooled platelet concentrate leukofiltered platelets platelet additive solution Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	buffy coat derived platelet component buffy coat pooled platelet concentrate leukofiltered platelets platelet additive solution Diseases of the blood and blood-forming organs RC633-647.5 Rakesh Kumar Hari Krishan Dhawan Ratti Ram Sharma Jyotdeep Kaur Buffy coat pooled platelet concentrate: A new age platelet component
description	BACKGROUND: Buffy coat pooled platelet concentrate (BCPP) is a new blood component mainly used in Europe, which has good attributes of both random donor platelets and apheresis platelets in terms of high platelet count, leukoreduced and available in emergency. We planned this study to compare quality parameters and biochemical activation markers among buffy coat pooled platelets and apheresis platelet concentrate (AP-PC) to establish the quality and safety of this new blood component during storage.MATERIALS AND METHODS: Three different preparations of BCPP were prepared: Nonleukoreduced (BCPP Part A), leukoreduced (BCPP Part B), and leukoreduced with platelet additive solution (PAS) (BCPP Part C) using a pool of 15 ABO-matched, nonreactive buffy-coats in each experiment to avoid any donor-related variations. Ten such experiments were done. Each BCPP was equivalent to 5 buffy coat units. Ten apheresis platelets were taken as control. Serial samplings were done on day 0, 3, and 5 of collection and were assessed for: volume, platelet count, white blood cell count, swirling, pH, sterility, glucose, lactate, soluble p-selectin, Interleukin (IL)-6, IL-1 β, and tumor necrosis factor alpha (TNF-α).RESULTS: BCPP Part C (leukoreduced with PAS) maintained the best quality parameters in terms of maintenance of pH, least lactate accumulation, least sP-selectin levels, and least accumulation of inflammatory mediators (IL-6, IL-1 β, and TNF-α) than the other groups >BCPP part B >AP-PC and >BCPP Part A. On day 5 of storage pH for BCPP Part A, Part B, Part C, and AP-PC was: 6.33, 6.42, 6.64, and 6.29, respectively, and soluble p-selectin (ng/ml) was 201 ± 22, 186 ± 11, 149 ± 18, 200 ± 23, respectively. BCPP Part B and AP-PC had comparable quality parameters and activation markers.CONCLUSIONS: Buffy coat pooled platelet has comparable and even better-quality control parameters (especially leukofiltered with PAS) than conventional platelet preparation and is a good alternative for meeting platelet transfusion requirements of critical patients during emergency hours in resource-constraint setting.
format	article
author	Rakesh Kumar Hari Krishan Dhawan Ratti Ram Sharma Jyotdeep Kaur
author_facet	Rakesh Kumar Hari Krishan Dhawan Ratti Ram Sharma Jyotdeep Kaur
author_sort	Rakesh Kumar
title	Buffy coat pooled platelet concentrate: A new age platelet component
title_short	Buffy coat pooled platelet concentrate: A new age platelet component
title_full	Buffy coat pooled platelet concentrate: A new age platelet component
title_fullStr	Buffy coat pooled platelet concentrate: A new age platelet component
title_full_unstemmed	Buffy coat pooled platelet concentrate: A new age platelet component
title_sort	buffy coat pooled platelet concentrate: a new age platelet component
publisher	Wolters Kluwer Medknow Publications
publishDate	2021
url	https://doaj.org/article/93805c7cc7b84529bc97c181e34cd573
work_keys_str_mv	AT rakeshkumar buffycoatpooledplateletconcentrateanewageplateletcomponent AT harikrishandhawan buffycoatpooledplateletconcentrateanewageplateletcomponent AT rattiramsharma buffycoatpooledplateletconcentrateanewageplateletcomponent AT jyotdeepkaur buffycoatpooledplateletconcentrateanewageplateletcomponent
_version_	1718431064510169088

Buffy coat pooled platelet concentrate: A new age platelet component

Ejemplares similares